


1653  
#10



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas J. Hudson, James C. Engert and Andrea Richter

Serial No.: 09/693,205

Group Art Unit: 1653

Filed: October 20, 2000

Examiner: C. Kam

For: Identification of ARSACS Mutations and Methods of Use Therefor

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>2/8/02</u>	<u>Stephanie L. Carta</u>
Date	Signature
Stephanie L. Carta	
Typed or printed name of person signing certificate	

RECEIVED  
FEB 28 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith is a Preliminary Amendment for filing in the above-identified application.

[ ] Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a Small Entity Statement previously submitted.

[ ] A Small Entity Statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

The fee has been calculated as shown below:

(COL. 1)	(COL. 2)	(COL. 3)	(COL. 4)	(COL. 5)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	39	MINUS	* 39	0
INDEP	16	MINUS	** 16	0
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

\* not fewer than 20  
\*\* not fewer than 3

SMALL ENTITY		
	RATE	ADDIT. FEE
X	\$ 9	\$
X	\$42	\$
+	\$140	\$

OTHER THAN SMALL ENTITY		
	RATE	ADDIT. FEE
X	\$18	\$ 0
X	\$84	\$ 0
+	\$280	\$

OR

TOTAL = \$ 0

TOTAL = \$ 0

Please charge Deposit Account No. 08-0380 for the following fees:

<input type="checkbox"/>	Petition for [ ] month Extension of Time	\$	_____
<input type="checkbox"/>	Amendment Fee	\$	_____
<input type="checkbox"/>	Other Fees:		
		\$	_____
		\$	_____
		TOTAL:	\$ <u>0</u>

A check is enclosed in payment of the following fees:

<input type="checkbox"/>	Petition for [ ] month Extension of Time	\$	_____
<input type="checkbox"/>	Amendment Fee	\$	_____
<input type="checkbox"/>	Other Fees:		
		\$	_____
		\$	_____
		TOTAL:	\$ <u>0</u>

[X] A general authorization is hereby granted to charge Deposit Account No. 08-0380 for any fees required under 37 C.F.R. 1.16 and 1.17 in order to maintain pendency of this application. A copy of this authorization is enclosed for accounting purposes.

Respectfully submitted,


HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Brian P. Turano  
Brian P. Turano  
Registration No.: P-50,734  
Telephone (978) 341-0036  
Facsimile (978) 341-0136

Concord, Massachusetts 01742-9133

Dated:

February 8, 2002



*Progmt B/# 10*  
*J 3/2/02*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas J. Hudson, James C. Engert and Andrea Richter

Serial No.: 09/693,205

Group Art Unit: 1653

Filed: October 20, 2000

Examiner: C. Kam

For: Identification of ARSACS Mutations and Methods of Use Therefor

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>2/8/02</u>	<u>Stephanie L Carta</u>
Date	Signature
Stephanie L. Carta	
Typed or printed name of person signing certificate	

PRELIMINARY AMENDMENT

RECEIVED

FEB 28 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Please amend the application as follows:

In the Specification

Please replace the paragraph at page 5, lines 3 through 15, with the following paragraph:

The invention further relates to a method of diagnosing or aiding in the diagnosis of neurodegenerative disease in an individual comprising obtaining a nucleic acid sample from the individual and determining the nucleotide present at nucleotide position 5254 of SEQ ID NO: 1, wherein the nucleotide position is numbered from the putative initiation codon, wherein presence of a thymine at said position is indicative of increased likelihood of neurodegenerative disease in the individual as compared with an appropriate control, *e.g.*, an individual having a cytosine at said position. The invention also relates to a method of diagnosing or aiding in the diagnosis of

B1